Bio-Path Holdings has secured $4 million in private placement to bolster its financial position for advancing clinical trials of its cancer treatments.
Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.